colorectal cancer
Conditions
Interventions
secondary prevention-FS:folic acid 0.8mg/day,sodium butyrate 700mg tid
primary prevention-control group:routine treatment
Group I-CV:calcium 1200mg/d vitamin D3 250 IU/d
primary prevention:folic acid 0.8mg/day
Group II-S:sodium butyrate 700mg tid
Group II-RT:therapeutic endoscopy and routine treatment
Group I-RT:routine treatment
Group II-FSCV:folic acid 0.8mg/day, sodium butyrate 700mg tid, c
Group II-CV:folic acid 0.8mg/day, sodium butyrate 700mg tid, c
Sponsors
Shanghai Jiaotong University School of Medicine Renji Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Sodium butyrate and folic acid group: patients meet the following criteria are enrolled: (1) 18-65 year-old; out-patient or in-patient patients; male or female; (2) Being excluded from the diagnoses of colorectal cancer, adnoma ploypi, or IBD by colonoscopy and pathology; (3) Being diagnosed of familial large intestine adenomatosis by family history or medical record; or being the first-degree relative of patients with familial adenomatous poliposis; (4) Those who voluntarily sign the consent form after being fully informed and understanding the purpose and procedures of the study, characters of the disease, effect of medications, methods of related examinations, and potential risk/benefits of the study. 2. folic acid group: patients meet the following criteria are enrolled: (1) 55-80 year-old; out-patient or in-patient patients;male or female (2) Being excluded from the diagnosis of adnoma ploypi by colonoscopy and pathology; (3) Being excluded from the diagnoses of familial large intestine adenomatosis or familial adenomatous poliposis by medical records or family history (5) Those who voluntarily sign the consent form after being fully informed and understanding the purpose and procedures of the study, characters of the disease, effect of medications, methods of related examinations, and potential risk/benefits of the study. 3. sodium butyrate or Calcium: patients meet the following criteria are enrolled: (1) 18-65 year-old; out-patient or in-patient patients; male or female (2) Being diagnosed of adnoma ploypi by colonoscopy and pathology; (3) Being excluded from the diagnosis of familial large intestine adenomatosis or familial adenomatous poliposis by medical records or family history; Those who voluntarily sign the consent form after being fully informed and understanding the purpose and procedures of the study, characters of the disease, effect of medications, methods of related examinations, and potential risk/benefits of the study.
Exclusion criteria
Exclusion criteria: Patients who are hypersensitive or intolerant to the drugs; Patients who are intolerant to another colonoscopy examination; Pregnant women, woman during breast-feeding period, or women with expect pregnancy; Patients with diabetes mellitus, severe heart or renal disease,or cancer history; Patients with malignant neoplasm, or suspicious colorectal cancer; Patients who are not able to cooperate; Individuals who are involved in designing, planning or performing this experiment; Patients with medical conditions who are not appropriate to participate the study Patients who are take aspirin or COX2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of polypi or carcinom;serum calcium; | — |
Secondary
| Measure | Time frame |
|---|---|
| stool sodium butyrate;serum folic aci; | — |
Countries
China
Contacts
Public ContactJingyuan Fang
Outcome results
None listed